ASH Conference Coverage

Dr. Tony Lin Summarizes Venclexta Data Presented at ASH

(DocWire News) Dec 21, 2020 - The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta.

read article

Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease

(MedPage Today) Dec 11, 2020 - Bispecific antibodies targeting CD20 and CD3 led to response rates as high as 90% in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who had received CAR T-cell therapy, according to preliminary clinical results.

read article (free registration required)

Advances in Blood Disorders Research Continue Despite COVID-19

(Fred Hutch) Dec 10, 2020 - The pandemic loomed large over ASH 2020, and not just because of its impact on the format.

read article

Nearly Half Of Lymphoma Patients Alive After Gilead’s CAR-T Therapy

(Pharmaphorum.com [UK]) Dec 9, 2020 - Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.

read article

Investigational CAR-T Cell Therapy Lisocabtagene Maraleucel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

(Curetoday.com) Dec 8, 2020 - The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.

read article

Duvelisib Response Rate 'Exciting' in Patients With r/r PTCL

(Medscape Medical News) Dec 8, 2020 - Duvelisib is demonstrating encouraging activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in a phase 2 trial, an investigator said.

read article (free registration required)

ASH 2020: GPRC5D Is a New Target of Interest for Multiple Myeloma

(DocWire News) Dec 9, 2020 - Ajai Chari, MD, PhD, of Mount Sinai Medical Center in New York, NY, discusses findings from a phase I study of the novel agent talquetamab, a first-in-class bispecific antibody that binds to GPRC5D and CD3, for the treatment of relapsed/refractory multiple myeloma.

read article

'Practice Changing': Ruxolitinib as Second-Line in Chronic GVHD

(Medscape Medical News) Dec 7, 2020 - New findings show that ruxolitinib (Jakafi) was superior to standard therapy in reducing symptoms of cGVHD in the second-line setting, and the results are potentially practice changing.

read article (free registration required)

Significant Number of Patients With Blood Cancers Deal With Depression or Anxiety Before or After Diagnosis, Highlighting ‘Critical’ Need for Mental Health Screening and Management

(Curetoday.com) Dec 8, 2020 - This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.

read article

Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission

(BMS) Dec 7, 2020 - Bristol Myers Squibb today announced new results from the QUAZAR® AML-001 study presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, evaluating Onureg®(azacitidine tablets; CC-486), an oral hypomethylating agent, as a treatment for adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery (CRi) following intensive induction chemotherapy.

read corporate press release

Roche Presents New Data From Its Bispecific Antibody Portfolio Across A Range Of Blood Cancers

(Roche) Dec 8, 2020 - Latest data to be presented at ASH 2020 includes results in non-Hodgkin lymphoma and heavily pre-treated multiple myeloma. Portfolio includes two CD20xCD3 bispecifics, mosunetuzumab and glofitamab, and first-of-its-kind FcRH5xCD3 bispecific antibody, cevostamab, building on Roche’s legacy of more than 20 years in antibody development.

read corporate press release

AL Amyloidosis Drug Results Shared at #ASH20

(SWOG) Dec 7, 2020 - Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that isatuximab, a monoclonal antibody approved for the treatment of multiple myeloma, can effectively treat relapsed refractory AL amyloidosis, findings to be announced at the 2020 Annual Meeting of the American Society of Hematology.

read article

ASH20: Genetic Mutations Could Help Predict Cancer Symptoms Decades in Advance

(OBR) Dec 8, 2020 - Using whole genome sequencing, researchers have traced the genetic origins of myeloproliferative neoplasms to early childhood, and in some cases all the way back to the time in utero. The findings, which were presented during the late breaking abstract session at the annual meeting of the American Society of Hematology, suggest that the genetic predictors of disease could be detected decades before patients experience disease symptoms, opening the door for preventive approaches.

read article

ASH20: ASCEMBL Trials Shows Asciminib Effectiveness as Third-Line Treatment for CML

(OBR) Dec 8, 2020 - The STAMP inhibitor asciminib appears safe and effective as third-line treatment for patients with chronic myeloid leukemia (CML) in chronic phase, according to findings from the phase 3 ASCEMBL trial. The results, which were presented as part of a late breaking abstract session at the annual meeting of the American Society of Hematology, demonstrated that asciminib was nearly twice as effective as a standard-of-care treatment regimen in achieving a major molecular response.

read article

Asciminib Found Safe and Effective for Hard-to-Treat Chronic Myeloid Leukemia

(ASH) Dec 8, 2020 - In a phase III trial called ASCEMBL, the experimental drug asciminib was nearly twice as effective as a standard-of-care treatment regimen for patients who had recurrent chronic myeloid leukemia (CML) despite two previous courses of tyrosine kinase inhibitors (TKIs). By specifically targeting the myristoyl pocket on the BCR-ABL1 protein, asciminib (known as a STAMP inhibitor) works through a different biological mechanism than existing TKIs, which comprise most available CML treatments.

read press release

Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis

(ASH) Dec 8, 2020 - Genetic mutations linked with cancer can occur during childhood or even before birth and proliferate in the body for many years before causing cancer symptoms, according to a new study. The study, which traced the genetic origins of a blood cancer in 10 individuals, suggests there may be untapped opportunities to detect cancer warning signs much earlier and potentially intervene to prevent or slow cancer development.

read press release

Gene Therapy for Hemophilia B Found Safe and Effective in First Phase III Trial

(ASH) Dec 8, 2020 - Study in ASH Late-Breaking Abstracts session shows most patients were able to stop intensive intravenous regimens, results may open doors for patients previously not included in gene therapy trials. The gene therapy etranacogene dezaparvovec substantially increased production of the blood clotting protein factor IX among 52 patients in the largest and most inclusive hemophilia B gene therapy trial to date.

read press release

In Multiple Myeloma, Cell Therapies Lead But Antibody Drugs Could Follow Fast

(BioPharma Dive) Dec 8, 2020 - Treatment for the blood cancer multiple myeloma has changed dramatically over the past two decades, and another significant shift looks to be just around the corner.

read article

Novartis Investigational STAMP Inhibitor Asciminib (ABL001) Shows Superior MMR Rate to Bosulif®* in Chronic Myeloid Leukemia Trial

(Novartis) Dec 8, 2020 - At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies.

read corporate press release

Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

(Yahoo! Finance) Dec 7, 2020 - Innovent Biologics, Inc. today announced data from two ongoing Phase 2 studies evaluating parsaclisib, an Incyte-discovered, potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular (CITADEL-203) and marginal zone (CITADEL-204) lymphomas.

read article
Next Page